The risks of AD (HR [95% CI]: 1.13 [0.76–1.69]) and VD (HR [95% CI]: 1.31 [0.88–1.97]) were not significantly higher with continuous use of GLP1 receptor agonists versus SGLT2 inhibitors. This evidence concerns the gene GLP1R and Alzheimer disease.